- Home
- LANV vs SKYE Comparison
LANV vs SKYE Comparison
Compare LANV & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- SKYE
- Stock Information
- Founded
- LANV 2015
- SKYE 2012
- Country
- LANV China
- SKYE United States
- Employees
- LANV N/A
- SKYE N/A
- Industry
- LANV Blank Checks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- SKYE Health Care
- Exchange
- LANV Nasdaq
- SKYE Nasdaq
- Market Cap
- LANV 219.4M
- SKYE 94.0M
- IPO Year
- LANV N/A
- SKYE N/A
- Fundamental
- Price
- LANV $1.85
- SKYE $2.67
- Analyst Decision
- LANV
- SKYE Buy
- Analyst Count
- LANV 0
- SKYE 6
- Target Price
- LANV N/A
- SKYE $18.67
- AVG Volume (30 Days)
- LANV 92.6K
- SKYE 167.7K
- Earning Date
- LANV 02-19-2025
- SKYE 02-09-2025
- Dividend Yield
- LANV N/A
- SKYE N/A
- EPS Growth
- LANV N/A
- SKYE N/A
- EPS
- LANV N/A
- SKYE N/A
- Revenue
- LANV $409,961,427.00
- SKYE N/A
- Revenue This Year
- LANV N/A
- SKYE N/A
- Revenue Next Year
- LANV $10.45
- SKYE N/A
- P/E Ratio
- LANV N/A
- SKYE N/A
- Revenue Growth
- LANV N/A
- SKYE N/A
- 52 Week Low
- LANV $0.91
- SKYE $2.25
- 52 Week High
- LANV $3.78
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- LANV 46.31
- SKYE 37.40
- Support Level
- LANV $1.69
- SKYE $2.31
- Resistance Level
- LANV $2.09
- SKYE $3.04
- Average True Range (ATR)
- LANV 0.24
- SKYE 0.30
- MACD
- LANV -0.04
- SKYE 0.07
- Stochastic Oscillator
- LANV 25.97
- SKYE 44.68
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.